Oral Insulin Delivery Platforms: Strategies To Address the Biological Barriers

DOI Web Site Web Site Web Site 1 Citations
  • Yufen Xiao
    Center for Nanomedicine Brigham and Women's Hospital Harvard Medical School Boston MA 02115 USA
  • Zhongmin Tang
    Center for Nanomedicine Brigham and Women's Hospital Harvard Medical School Boston MA 02115 USA
  • Junqing Wang
    Center for Nanomedicine Brigham and Women's Hospital Harvard Medical School Boston MA 02115 USA
  • Chuang Liu
    Center for Nanomedicine Brigham and Women's Hospital Harvard Medical School Boston MA 02115 USA
  • Na Kong
    Center for Nanomedicine Brigham and Women's Hospital Harvard Medical School Boston MA 02115 USA
  • Omid C. Farokhzad
    Center for Nanomedicine Brigham and Women's Hospital Harvard Medical School Boston MA 02115 USA
  • Wei Tao
    Center for Nanomedicine Brigham and Women's Hospital Harvard Medical School Boston MA 02115 USA

Abstract

<jats:title>Abstract</jats:title><jats:p>Diabetes mellitus is a lifelong metabolic disease that requires frequent subcutaneous injections of insulin. However, this method of administration can be associated with patient discomfort and local tissue infection. Oral delivery of insulin has been pursued as a more convenient method for diabetes treatment, given its likely superior patient compliance and convenience as well as cost‐effectiveness. However, various biological barriers hinder the clinical translation of oral insulin. The rapid development of nanotechnology over the last decade offers great promise in improving the bioavailability of oral insulin. This Minireview provides an overview of biological barriers to oral insulin delivery, summarizes significant technological advances, and outlines future perspectives in oral insulin formulations as well as their hypoglycaemic effects.</jats:p>

Journal

Citations (1)*help

See more

Report a problem

Back to top